3 Results for "

extracellular ligand-binding domain

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "extracellular ligand-binding domain" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99165
CAS No.: 1036734-93-6

Target:  

IGF-1R TSH Receptor

Research Areas:  

Endocrinology

Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
loading...
    loading...
Cat. No.: HY-108822
CAS No.: 501081-76-1
Purity:  ≥95.0%
Synonyms: Arcalyst; IL 1 Trap; Interleukin 1 Trap

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
loading...
    loading...
Cat. No.: HY-P991106
Synonyms: LY-3076226 antibody

Target:  

FGFR ADC Antibodies

Research Areas:  

Cancer

IMC-D11 (LY-3076226 antibody) is an anti-FGFR3 IgG1 monoclonal antibody with an EC50 of approximately 0.1 nM against hFGFR3b and hFGFR3c. IMC-D11 inhibits the growth of FGFR3-dependent lung adenocarcinoma in mouse models and shows no effect on tumors that do not express FGFR3. IMC-D11 can serve as an ADC Antibody for ADC synthesis, such as LY3076226. IMC-D11 is applicable to research related to urothelial carcinoma, multiple myeloma, lung adenocarcinoma, as well as advanced or metastatic cancers .
loading...
    loading...